Last 19.00 GBp
Change Today -0.25 / -1.30%
Volume 503.8K
AGY On Other Exchanges
As of 11:59 AM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

allergy therapeutics plc (AGY) Snapshot

19.25 GBp
Previous Close
19.25 GBp
Day High
19.25 GBp
Day Low
18.75 GBp
52 Week High
03/7/14 - 32.75 GBp
52 Week Low
11/11/13 - 6.75 GBp
Market Cap
Average Volume 10 Days
0.0042 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

allergy therapeutics plc (AGY) Related Businessweek News

No Related Businessweek News Found

allergy therapeutics plc (AGY) Details

Allergy Therapeutics plc, a specialty pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical vaccine products for the immunological treatment of allergic conditions primarily in Europe. The company offers vaccinations in various forms, including allergen-specific, patient-specific, and standard products in injectable and sublingual presentations. Its products portfolio comprises marketed products containing allergoids (modified allergens), tyrosine depot, and monophosphoryl-lipid A adjuvant. The company’s primary product consists of the Pollinex Quattro, an injectable short course vaccine for the treatment of allergic conditions. Its longer course products comprise Pollinex, TA Mix top, and Venomil. The company also offers sublingual product, including Oralvac Compact; probiotic products, such as Kallergen-Th, ATI Prob and Pollagen; and Acarovac Plus, a novel tyrosine-adsorbed, modified-allergen product developed for treatment of perennial mite allergy. Its licensed product includes DAP, a product for exclusive use in the diagnosis of type I or immediate hypersensitivity to benzylpenicillin and related antibiotics (betalactams) by means of cutaneous tests (prick and intradermal). Allergy Therapeutics plc was founded in 1934 and is headquartered in Worthing, the United Kingdom.

376 Employees
Last Reported Date: 10/15/13
Founded in 1934

allergy therapeutics plc (AGY) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 218.0K GBP
Finance Director, Company Secretary and Direc...
Total Annual Compensation: 140.7K GBP
Compensation as of Fiscal Year 2013.

allergy therapeutics plc (AGY) Key Developments

Allergy Therapeutics plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended December 31, 2013

Allergy Therapeutics plc announced unaudited consolidated earnings results for the six months ended December 31, 2013. For the period, the company's revenue was £27,166,000 against £25,749,000 a year ago. Operating profit was £6,651,000 against £5,277,000 a year ago. Profit before tax was £6,523,000 against £5,141,000 a year ago. Profit for the period was £6,226,000 against £4,952,000 a year ago. Diluted earnings per share were 1.47 pence against 1.17 pence a year ago. Net cash generated by operating activities was £4,737,000 against £4,100,000 a year ago. Payments for property plant and equipment were £390,000 against £227,000 a year ago.

Health Canada Approves Submission of Allergy Therapeutics's Clinical Trial Application

Allergy Therapeutics announced that the Canadian Health Authority, Health Canada, has approved the Company's proposal to submit a full Clinical Trial Application (CTA) for a new clinical efficacy study (G304) for Pollinex Quattro Grass MATA MPL (0.5ml). Health Canada reviewed the proposal and all supporting data at a meeting with the Company on 18 February 2014. The meeting builds on the discussions held with the FDA, which resulted in the lifting of the clinical hold on the company's clinical studies using vaccines containing the adjuvant monophosphoryl lipid A (MPL) in August 2012. These decisions enable the Company to plan the start of the G304 study, which will involve two clinical sites in the USA as well as one in Canada. The study, involving over 600 patients, will use multiple Environmental Exposure Chambers (EECs), allowing for controlled allergen exposure, to study the response to treatment with the new Pollinex Quattro Grass MATA MPL (0.5ml) compared to Grass MATA (0.5 ml) and placebo. Patients will be exposed to grass pollen in the EECs before treatment and then after treatment, with the ultra-short course of four subcutaneous injections. An evaluation of long term efficacy, 12 months post treatment, in patients enrolled for the G304 study will also be made in the EECs. The safety and efficacy advantages of the addition of MPL to the MATA products, previously seen in Allergy Therapeutics' Pollinex QuattroRagweed MATA MPL (0.5 ml), will be further determined during the G304 study.

Allergy Therapeutics plc to Report First Half, 2014 Results on Mar 24, 2014

Allergy Therapeutics plc announced that they will report first half, 2014 results on Mar 24, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGY:LN 19.00 GBp -0.25

AGY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ALK-Abello A/S kr761.00 DKK -6.00
DBV Technologies SA €16.50 EUR +0.12
Merck & Co Inc $57.33 USD -0.44
Sanofi €77.05 EUR -0.08
Stallergenes SA €57.96 EUR -0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation AGY Industry Range
Price/Earnings 46.1x
Price/Sales 2.0x
Price/Book 3.8x
Price/Cash Flow 44.3x
TEV/Sales 2.0x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGY THERAPEUTICS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at